Invisicare: Advancing Transdermal Drug Delivery
Innovating Transdermal Solutions for Small Molecule Therapies
Invisicare: Advancing Transdermal Drug Delivery
The promising results with Invisicare transdermal delivery of obesity drugs paves the way for Skinvisible’s continued development and optimization of our innovative drug delivery technology for a broader application for other disorders where small molecules are used (generally conceded < 1000 g/mole). Transdermal delivery provides a non-invasive administration as an alternative to conventional needle injections.
Invisicare: Advancing Transdermal Small Molecule Delivery
Skinvisible's Invisicare technology represents a breakthrough in small molecule transdermal delivery, opening significant development opportunities across multiple therapeutic areas including oncology and neurodegenerative diseases. Our innovative approach has the potential to dramatically improve treatment options for patients by enhancing medication delivery systemically through the skin. Skinvisible is actively seeking strategic partnerships and licensing opportunities to expand Invisicare's applications into novel therapeutic areas and bring these transformative solutions to market.
PIPELINE:
PARTNERSHIPS AND LICENSING OPPORTUNITIES
Partner With Us:
Skinvisible is seeking strategic partners and licensees for our innovative Invisicare formulations.